黄芩苷胶囊联合胸腺法新治疗慢性乙型肝炎的临床研究

目的探讨黄芩苷胶囊联合胸腺法新治疗慢性乙型肝炎的临床效果。方法选取2015年1月—2017年6月四川绵阳四〇四医院收治的慢性乙型肝炎患者134例,随机分成对照组(67例)和治疗组(67例)。对照组皮下注射注射用胸腺法新治疗,1.6 mg/次,2次/周。治疗组在对照组基础上口服黄芩苷胶囊,2粒/次,3次/d,连续治疗6个月。观察两组患者临床疗效,同时比较治疗前后两组患者肝功能指标、病毒标志物转阴率及还原型谷胱甘肽(GSH)、GSH/氧化型谷胱甘肽(GSSG)、白介素-6(IL-6)、IL-17和CD4+/CD8+水平。结果治疗后,对照组临床有效率为80.6%,显著低于治疗组的92.5%,两组比较差异具有统计学意义(P0.05)。治疗后,两组患者肝功能指标总胆红素(TBIL)、天门冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)血清浓度较治疗前均显著降低(P0.05),且治疗组患者肝功能指标明显低于对照组(P0.05)。治疗后,治疗组乙型肝炎病毒脱氧核糖核酸(HBV DNA)、乙肝病毒e抗原(HBeAg)和乙肝表面抗原(HBsAg)转阴率分别为91.0%、94.0%、88.1%,显著高于对照组的77.6%、82.1%、74.6%,两组比较差异具有统计学意义(P0.05)。治疗后,两组患者血清GSH浓度、GSH/GSSG比值和外周血CD4+/CD8+比值均显著上升(P0.05),血清IL-6、IL-17水平均显著下降(P0.05),且治疗组上述指标比对照组改善更明显(P0.05)。结论黄芩苷胶囊联合胸腺法新治疗慢性乙型肝炎可明显改善患者症状,减轻肝损伤,维持免疫平衡,抗HBV效果显著。

Clinical study on Baicalin Capsules combined with thymalfasin in treatment of chronic hepatitis B

Objective To investigate the clinical effect of Baicalin Capsules combined with thymalfasin in treatment of chronic hepatitis B.Methods Patients (134 cases) with chronic hepatitis B in Sichuan Mianyang 404 Hospital from January 2015 to June 2017 were randomly divided into control (67 cases) and treatment (67 cases) groups. Patients in the control group were sc administered with Thymalfasin for injection, 1.6 mg/time, twice every week. Patients in the treatment group were po administered with Baicalin Capsules on the basis of the control group, 2 grains/time, three times daily, and they were treated for 6 months. After treatment, the clinical efficacy was evaluated, and the liver function indexes, the negative conversion rates of viral markers, and GSH, GSH/GSSG, IL-6, IL-17, and CD4⁺/CD8⁺ levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 80.6%, which was significantly lower than 92.5% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the serum TBIL, AST and ALT concentration in two groups was significantly decreased (P<0.05), and the liver function indexes in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the negative conversion rates of HBV DNA, HBeAg and HBsAg in the treatment group were 91.0%, 94.0%, and 88.1%, which were significantly higher than 77.6%, 82.1%, and 74.6% in the control group, respectively, and there were differences between two groups (P<0.05). After treatment, the GSH concentration, GSH/GSSG, and CD4⁺/CD8⁺of peripheral blood levels in two groups were significantly increased (P<0.05), but IL-6 and IL-17 levels were significantly decreased (P<0.05), and these indexes in the treatment group were significantly better than those in the control group (P<0.05). Conclusion Baicalin Capsules combined with thymalfasin in treatment of chronic hepatitis B can obviously improve the symptoms, relieve liver injury, maintain immune balance, and has obvious anti-HBV effect.